Welcome ....................................................................................................................................p. 4
  - IFPA President
  - Scientific Executive Committee

Committees ....................................................................................................................................p. 5

Scientific Program .....................................................................................................................p. 6

Registration ...............................................................................................................................p. 12

Important Addresses ..................................................................................................................p. 12

Social Program ..........................................................................................................................p. 13

General Information ..................................................................................................................p. 16

Stockholm and Sweden .............................................................................................................p. 17

Abstracts ....................................................................................................................................p. 19

Patron of the 2nd World Psoriasis & Psoriatic Arthritis Conference

His Majesty King Carl Gustav
Dear Friend,

On behalf of the International Federation of Psoriasis Associations, IFPA, it is my great honor to invite you to the 2nd World Psoriasis and Psoriatic Arthritis Conference 2009, which will take place in Stockholm, Sweden, June 24-28, 2009.

In 2006 IFPA organized, together with leading dermatologists and rheumatologists, the 1st Psoriasis and Psoriatic Arthritis Conference in Stockholm. The purpose was to assemble dermatologists and rheumatologists and, for the first time ever, have a joint high-level scientific discussion and approach to our disease. The conference became a great success and IFPA was therefore asked to organize a second conference in 2009.

The theme for 2009 is "Psoriasis - Skin and Beyond" which recognizes the many diverse and emerging issues involved with psoriasis and associated conditions.

We now know that there are several other medical problems than psoriasis arthritis linked to psoriasis, e.g. risk for cardiovascular conditions, eye problems, inflammatory bowel diseases, diabetes and obesity. The purpose of the conference is to bring all aspects of the psoriasis patient together in one conference and from a patient’s point of view discuss new scientific facts and studies.

The scientific program is strongly influenced by an IFPA Worldwide survey conducted in 2008, where important topics have been identified from the patient’s perspective. On the basis of the survey findings, the Scientific Executive Committee has been able to create a conference program which covers almost all aspects of the psoriasis disease from a scientific point of view. We have also included a complementary program for allied health professionals; nurses, physiotherapists and others.

I am therefore confident that the 2nd World Conference will be a common platform for all specialists involved in research and treatment of our disease, in their efforts to give the psoriasis patients around the world better and more effective treatment methods and a better quality of life. I also hope the conference will be a major contribution to our joint efforts to have psoriasis recognized as a serious systemic chronic inflammatory noncommunicable disease by all responsible national authorities and the World Health Organization, WHO.

Yours sincerely,

Lars Ettarp
President of IFPA

Dear Colleague,

In 2006, the International Federation of Psoriasis Associations, IFPA, organized the 1st World Psoriasis and Psoriatic Arthritis Conference in Stockholm. About 700 delegates from 47 countries attended the conference which provided a unique environment for open exchange between health care professionals from various backgrounds who care for psoriasis patients. The success of the meeting documented the need for an ongoing interaction and communication that will allow researchers, clinicians and patients to keep pace with the tremendous progress that is unfolding in all areas related to psoriasis.

It is now our great pleasure and honour to invite you to the 2nd World Psoriasis and Psoriatic Arthritis Conference that will take place in Stockholm in June 2009. We have developed an ambitious conference program that addresses a broad spectrum of scientific, clinical and practical, aspects of psoriasis and related disorders. The lectures will be delivered by leading world experts who will share their knowledge and experience with opportunities for interactive discussions. In addition, a call for abstracts on relevant psoriasis issues will provide a forum for presentation of the most recent progress in clinical and experimental research in order to facilitate additional discussion and collaboration.

As such, we expect that the conference program will combine cutting edge presentations with a learning environment that will maximize interaction between physicians and scientists. It is also anticipated that these interactions, will enhance communication between patients and health professionals and catalyze new research efforts in psoriatic disease.

We look forward to welcoming you at the 2nd World Psoriasis and Psoriatic Arthritis Conference in Stockholm and we are confident that you will find the program stimulating and enjoyable.

Sincerely,

Prof. Joerg C. Prinz
President of the 2nd World Psoriasis and Psoriatic Arthritis Conference 2009 Chairman of the Scientific Executive Committee

Prof. Mona Ståhle
Co-chair of the Scientific Executive Committee

Prof. Christopher Ritchlin
Co-chair of the Scientific Executive Committee
Committees

Scientific Executive Committee

Chairman
Prof. Joerg C. Prinz
University of Munich, Munich, GERMANY

Co-Chair
Prof. Mona Ståhle
Karolinska Institutet, Stockholm, SWEDEN

Co-Chair
Prof. Christopher Ritchlin
University of Rochester Medical Center, New York, USA

Council of Scientific Advisors

Dr. Dominique Baeten
University of Amsterdam, Netherlands

Dr. Juan Canete
Hospital Clinic, Spain

Prof. Enno Christophers
University of Schleswig Holstein Kiel, Germany

Prof. Sergio Chimenti
University of Rome Tor Vergata, Italy

Prof. Louis Dubertret,
Psoriasis International Network, France

Prof. Luis Espinosa
LSU Health Sciences Center, USA

Ass. Prof. David Fiorentino
Stanford school of medicine, Spain

Ass. Prof. Amit Garg
University of Massachusetts, USA

Dr. Wayne Gulliver,
NewLab Clinical research, Canada

Dr. Elaine Husni
Cleveland Clinic, USA

Prof. Knud Kragballe
Århus University Hospital, Denmark

Prof. Richard Langley,
Dalhousie University, USA

Prof. Robert Landew
University Hospital Maastricht, Netherlands

Dr. Ennio Lubrano
Scientific Institute of Telese terme, Italy

Prof. Dennis McGonagle
University of Leeds, UK

Prof. Ulrich Mrowietz
University of Kiel, Germany

Prof. Mikkel Ostergaard,
Copenhagen University Hospitals at Herlev and Hvidovre, Denmark

Dr. Ignazio Olivieri,
San Carlo Hospital, Italy

Prof. Constantino Pitzalis
Barts and the London School of Medicine and Dentistry, UK

Ass. Prof. Louis Puig,
Universitat Autònoma de Barcelona, Spain

Dr. Proton Rahman
Memorial University of Newfoundland Canada

Dr. Murlidhar Rajagopalan
Apollo hospitals, India

Dr. Anthony Russell
University of Alberta, Canada

Prof. Thomas Ruzicka,
University of Munich, Germany

Prof. Raffaele Scarpa
University of Napoli, Italy

Dr. Enrique Soriano
Hospital Italiano de Buenos Aires, Argentina

Paul Peter Tak
University of Amsterdam Netherlands

Dr. Tsan-Fang Tsai
National Taiwan University Hospital, Taiwan

Prof. Gail Todd
University of Cape Town, South Africa

Dr. Kurt de Vlam
University Hospitals Leuven, Belgium

Scientific Program Committee

Dermatology
Prof. Kenneth Gordon,
Loyola University Medical Center, Illinois, USA

Prof. Christopher Griffith,
University of Manchester, Manchester, UK

Prof. Peter van de Kerkhof,
University Medical Centre Nijmegen, Nijmegen, The Netherlands

Dr. Alan Menter,
Baylor Research Institute, Dallas, USA

Rheumatology
Prof. Dafna Gladman,
Toronto Western Hospital, Toronto, CANADA

Dr. Philip Helliwell,
University of Leeds, Leeds, UK

Prof. Arthur Kavanaugh,
The University of California, San Diego, USA

Dr. Philip Mease
Seattle Rheumatology Associates, USA

IFPA Medical Advisors

Prof. Mark Lebwohl, USA

Prof. Peter van de Kerkhof, The Netherlands

Organizing Committee

Chairman
Prof. Joachim Barth,
Treasurer of IFPA, GERMANY

Lars Ettarp,
President of IFPA, SWEDEN

Dr. Hoseah Waweru,
Vice President of IFPA, KENYA

Kathleen Gallant,
Secretary of IFPA, USA

Valgerdur Audunsdottir,
Member at large of IFPA, ICELAND

IFPA Secretariat
# Scientific Program

<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
<th>Time</th>
<th>COMPLEMENTARY PROGRAM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>THURSDAY JUNE 25TH</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>COMPLEMENTARY PROGRAM, room 307</strong></td>
</tr>
<tr>
<td>07.30</td>
<td>Registration</td>
<td>13.30 – 15.30</td>
<td>Chair: Hoseah Waweru</td>
</tr>
<tr>
<td>08.30 – 09.00</td>
<td>Opening ceremony</td>
<td>20 minutes</td>
<td>Introduction to the complementary program</td>
</tr>
<tr>
<td></td>
<td>Speakers: Lars Ettarp President of IFPA, Prof. Göran Hansson, Secretary of the Nobel Committee for physiology or medicine and member of the Board of Directors of the Nobel Foundation, Prof. Juerg C. Prinz, Prof. Christopher Ritchlin</td>
<td>20 minutes</td>
<td>Speaker: Prof. Joachim Barth</td>
</tr>
<tr>
<td>09.00 – 10.00</td>
<td><strong>PLENARY 1. PSORIASIS: MORE THAN SKIN DEEP</strong></td>
<td>40 minutes</td>
<td>From a physiotherapeutic point of view</td>
</tr>
<tr>
<td></td>
<td>Chairs: Prof. Dennis McGonagle and Dr. David Fiorentino</td>
<td></td>
<td>Speaker: Prof. Christina H. Opava</td>
</tr>
<tr>
<td></td>
<td>20 minutes</td>
<td>20 minutes</td>
<td>Early diagnosis of psoriatic arthritis: Is enthesitis the primary lesion? Speaker: Dr. Philip Hellwell</td>
</tr>
<tr>
<td></td>
<td>Psoriasis: what is it? Classification and phenotype Speaker: Dr. Alan Menter</td>
<td>20 minutes</td>
<td>Looking at it: Psoriasis and eye disease Speaker: Dr. Jim Rosenbaum</td>
</tr>
<tr>
<td></td>
<td>Skin and bone: The pathogenetic relationship between psoriasis and psoriatic arthritis Speaker: Prof. Christopher Ritchlin</td>
<td>20 minutes</td>
<td>Looking at it: Psoriasis and eye disease Speaker: Dr. Jim Rosenbaum</td>
</tr>
<tr>
<td></td>
<td>The collateral damage: Co-morbidities and life expectancy Speaker: Dr. Joel Gelfand</td>
<td>20 minutes</td>
<td>Looking at it: Psoriasis and eye disease Speaker: Dr. Jim Rosenbaum</td>
</tr>
<tr>
<td>10.00 – 10.30</td>
<td>Poster Session and Exhibits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 – 12.00</td>
<td><strong>PLENARY 2. LIVING WITH PSORIASIS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr. Hoseah Waweru and Dr. Elaine Husni</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20 minutes</td>
<td>20 minutes</td>
<td>The outcasts: Living with stigmatization Speaker: Prof. G. Schmid-0tt</td>
</tr>
<tr>
<td></td>
<td>Making it worse: Triggers and risk factors for psoriasis and psoriatic arthritis Speaker: Dr. Luigi Naldi</td>
<td>20 minutes</td>
<td>Making it worse: Triggers and risk factors for psoriasis and psoriatic arthritis Speaker: Dr. Luigi Naldi</td>
</tr>
<tr>
<td></td>
<td>Stressing psoriasis: the psychosocial impact Speaker: Dr. Francesca Sampogna</td>
<td>20 minutes</td>
<td>Stressing psoriasis: the psychosocial impact Speaker: Dr. Francesca Sampogna</td>
</tr>
<tr>
<td></td>
<td>Patient education: What do psoriasis patients need to learn? Speaker: Dr. Anna-Lene Krogstad</td>
<td>20 minutes</td>
<td>Patient education: What do psoriasis patients need to learn? Speaker: Dr. Anna-Lene Krogstad</td>
</tr>
<tr>
<td>12.00 – 13.30</td>
<td>Posters/Exhibits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15 – 13.15</td>
<td>Lunch seminar - Schering-Plough, The Auditorium, Norra Latin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>New Views on Nail Anatomy and Psoriasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30 – 15.30</td>
<td><strong>PLENARY 3. PSORIASIS: GOING ASTRAY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Kurt de Vlam and Prof. Jean Saurat</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20 minutes</td>
<td>20 minutes</td>
<td>Early diagnosis of psoriatic arthritis: Is enthesitis the primary lesion? Speaker: Dr. Philip Hellwell</td>
</tr>
<tr>
<td></td>
<td>Looking at it: Psoriasis and eye disease Speaker: Dr. Jim Rosenbaum</td>
<td>20 minutes</td>
<td>Looking at it: Psoriasis and eye disease Speaker: Dr. Jim Rosenbaum</td>
</tr>
</tbody>
</table>

---

**WEDNESDAY JUNE 24TH**

<table>
<thead>
<tr>
<th>Time</th>
<th><strong>GENERAL PROGRAM</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-17.00</td>
<td>Pre-Conference meetings</td>
</tr>
<tr>
<td>15.00-18.00</td>
<td><strong>REGISTRATION</strong></td>
</tr>
<tr>
<td>18.00-19.30</td>
<td>Welcome reception</td>
</tr>
</tbody>
</table>

---

**THURSDAY JUNE 25TH**

<table>
<thead>
<tr>
<th>Time</th>
<th><strong>GENERAL PROGRAM</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 09.00</td>
<td>Opening ceremony</td>
</tr>
<tr>
<td>09.00 – 10.00</td>
<td><strong>PLENARY 1. PSORIASIS: MORE THAN SKIN DEEP</strong></td>
</tr>
<tr>
<td>10.00 – 10.30</td>
<td>Poster Session and Exhibits</td>
</tr>
<tr>
<td>10.30 – 12.00</td>
<td><strong>PLENARY 2. LIVING WITH PSORIASIS</strong></td>
</tr>
<tr>
<td>12.00 – 13.30</td>
<td>Posters/Exhibits</td>
</tr>
<tr>
<td>12.15 – 13.15</td>
<td>Lunch seminar - Schering-Plough, The Auditorium, Norra Latin</td>
</tr>
<tr>
<td>13.30 – 15.30</td>
<td><strong>PLENARY 3. PSORIASIS: GOING ASTRAY</strong></td>
</tr>
</tbody>
</table>

---

**COMPLEMENTARY PROGRAM**
<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
<th>Time</th>
<th>COMPLEMENTARY PROGRAM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Standing straight: spinal disease in psoriasis</td>
<td>20 minutes</td>
<td>Swedish treatment centers – a holistic approach</td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Dafna Gladman</td>
<td></td>
<td>Speaker: Lars Ettarp, President of the Swedish Psoriasis Association</td>
</tr>
<tr>
<td>20 minutes</td>
<td>Psoriasis treatment and the risk of infection, cancer and lymphoma: what do registries tell us?</td>
<td></td>
<td>20 minutes</td>
</tr>
<tr>
<td>20 minutes</td>
<td>Psoriasis and cardiovascular complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 minutes</td>
<td>Abstract presentations <strong>Abstract No. 41 - Metabolic syndrome at psoriasis onset and at long-term follow-up of psoriasis: A prospective cohort study</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Abstract No. 42 - Inflammation: A pivotal link between psoriatic arthritis and atherosclerosis including case reports</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td>Coffee/Posters/Exhibits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00 – 16.30</td>
<td>Key note lecture <strong>THE INFLAMMATORY BASIS OF ATHEROSCLEROSIS: Aggravation by chronic immune mediated inflammatory disorders?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Göran Hansson</td>
<td>16.45 – 17.45</td>
<td>Satellite Symposium - Wyeth, room 202</td>
</tr>
<tr>
<td></td>
<td><strong>More than skin deep: Changing management practises in psoriatic disease</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FRIDAY JUNE 26TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>GENERAL PROGRAM</th>
<th>Time</th>
<th>COMPLEMENTARY PROGRAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30 – 08.30</td>
<td>Posters/Exhibits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30 – 09.00</td>
<td>Key note lecture <strong>PSORIASIS THROUGH GENERATIONS: the genetic predisposition of psoriasis and psoriatic arthritis</strong></td>
<td></td>
<td><strong>PLENARY 4. THE PSORIASIS FAMILY</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. James T. Elder</td>
<td>09.00 – 10.00</td>
<td><strong>PLENARY 5. PSORIASIS: FROM BENCH TO PATIENT</strong></td>
</tr>
<tr>
<td>20 minutes</td>
<td>Family members and partners: 1st degree sufferers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Andrew Y Finlay</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 minutes</td>
<td>Family planning and psoriasis treatment: contraception, pregnancy and lactation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Ass. Prof. Alexa Kimball</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 minutes</td>
<td>Psoriasis and psoriatic arthritis in childhood: therapeutic challenges</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Amy Paller</td>
<td>10.00 – 10.30</td>
<td>Poster Session and Exhibits</td>
</tr>
<tr>
<td>10.30 – 12.00</td>
<td><strong>PLENARY 5. PSORIASIS: FROM BENCH TO PATIENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr. Proton Rahman and Chair Prof. Herve Bachelez</td>
<td>10.30 – 12.00</td>
<td><strong>COMPLEMENTARY PROGRAM room 307</strong></td>
</tr>
<tr>
<td>20 minutes</td>
<td>Step by step: Dissecting pathogenic events in psoriasis</td>
<td></td>
<td><strong>Topical therapy - Easy, available and not to be forgotten</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Frank Nestle</td>
<td>20 minutes</td>
<td><strong>Photo therapy and photo chemotherapy - When topical treatment are insufficient</strong></td>
</tr>
<tr>
<td>20 minutes</td>
<td>Cytokines and synovial biology</td>
<td></td>
<td><strong>Photosensitivity and photo allergy</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Ian B McNiches</td>
<td>20 minutes</td>
<td><strong>Systemic therapy - i.e. Biologics, Methotrexate, Cyclosporine, Retinoids</strong></td>
</tr>
<tr>
<td>20 minutes</td>
<td>MicroRNAs: regulators of skin inflammation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Mona Stähle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 minutes</td>
<td>Psoriatic autoantigens: a chance for vaccination?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Prof. Joerg C. Prinz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>GENERAL PROGRAM</td>
<td>Time</td>
<td>COMPLEMENTARY PROGRAM</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>10 minutes</td>
<td><strong>Abstract presentation</strong>&lt;br&gt;Abstract No. 4 - The molecular profile of psoriatic skin in responders to ustekinumab or etanercept following twelve weeks of treatment: Results from the ACCEPT Trial</td>
<td>12.00 – 13.30</td>
<td>Posters/Exhibits</td>
</tr>
<tr>
<td></td>
<td><strong>Abstract presentations</strong>&lt;br&gt;Abstract No. 52 - Achieving minimal disease activity (MDA) criteria decreases progression of joint damage in PSA&lt;br&gt;Abstract No. 114 - Statins in the treatment of psoriasis - friend or foe?</td>
<td>15.30 – 16.00</td>
<td>Poster Session and Exhibits</td>
</tr>
<tr>
<td>16.00 – 16.30</td>
<td><strong>Key note lecture</strong>&lt;br&gt;OBESITY, METABOLIC SYNDROME AND PSORIASIS: the slimmer - the better?&lt;br&gt;Speaker: Prof. Peter Arner</td>
<td>16.45 – 17.45</td>
<td><strong>Satellite Symposium - Abbott, The Auditorium, Norra Latin</strong>&lt;br&gt;Dermatology &amp; Rheumatology: Sharing the experience of using anti-TNFs in psoriatic diseases</td>
</tr>
<tr>
<td><strong>SATURDAY JUNE 27TH</strong></td>
<td></td>
<td>07.30 – 08.30</td>
<td>Posters/Exhibits</td>
</tr>
<tr>
<td>08.30 – 09.30</td>
<td><strong>PLENARY 7. PSORIASIS CARE</strong>&lt;br&gt;Chairs: Prof. Luis Puig and Prof. Mikkel Ostergaard</td>
<td>09.30 – 10.00</td>
<td><strong>Key note lecture</strong>&lt;br&gt;THE REVOLUTION IN PSORIASIS TREATMENT: Selective interference with pathogenesis.&lt;br&gt;Speaker: Prof. James G. Krueger</td>
</tr>
<tr>
<td>10.00 – 10.30</td>
<td>Posters/Exhibits</td>
<td>10.30 – 12.00</td>
<td><strong>PLENARY 8. HEALTH ECONOMICS AND HEALTH POLITICS</strong>&lt;br&gt;Chairs: Dr. Luis R. Espinoza and Prof. Gail Todd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Abstract presentations</strong>&lt;br&gt;Abstract No. 62 - Achieving minimal disease activity (MDA) criteria decreases progression of joint damage in PSA&lt;br&gt;Abstract No. 114 - Statins in the treatment of psoriasis - friend or foe?</td>
</tr>
<tr>
<td>Time</td>
<td>GENERAL PROGRAM</td>
<td>Time</td>
<td>COMPLEMENTARY PROGRAM</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 20 minutes | The economic burden of psoriasis and psoriatic arthritis  
Speaker: Prof. Arthur Kavanaugh | 13.30 – 15.30 | **COMPLEMENTARY PROGRAM room 307**  
Chair: Prof. Joachim Barth |
| 20 minutes | Community participation: Who benefits?  
Speaker: Dr. Will Taylor | 20 minutes | Pustulosis palmoplantaris - Painful and hard to treat  
Speaker: Dr. Birgitta Wilson Cläreus |
| 20 minutes | Abstract presentation  
Abstract No: 115 - Quality of care and research profiles. Results of an International Psoriasis Council (IPC) exercise | 20 minutes | Psoriasis does not stop at the ankles - The importance of podiatric care  
Speaker: Gunnel Köhler |
| 10 minutes | Practical issues during sytemic treatment  
Speaker: Prof. Paul Emery | 20 minutes | Drugs/Medications that deteriorates psoriasis  
Speaker: Ms Karina Jackson |
| 10 minutes | Abstract presentation  
Abstract No: 99 - Development of a composite disease activity score in psoriatic arthritis | 20 minutes | PASI-score – educational session  
Speaker: Dr. Anne-Lene Krogstad |
| 12.00 – 13.30 | Posters/Exhibits                                                                 | 15.00 – 15.30 | Poster Session and Exhibits |
| 12.15 – 13.15 | Lunch seminar - International Psoriasis Council, IPC, hall C  
Meet the experts, a case-based learning discussion | 15.30 – 16.30 | **CONCLUDING LECTURES**  
Chairs: Prof. Paul P. Tak and Prof. Richard Langley |
| 13.30 – 15.00 | **PLENARY 9. ASSESSING SEVERITY, FOLLOWING PROGRESSION**  
Chairs: Professor Sergio Chimenti and Dr. Ignazio Olivieri | 15.30 – 16.30 | Psoriatic arthritis: coping or curing?  
Speaker: Dr. Douglas Veale |
| 20 minutes | Psoriasis - defining severity. National Psoriasis Foundation clinical consensus on disease severity  
Speaker: Prof. Mark Lebwohl | 20 minutes | Psoriasis care: Quo vadis?  
Prof. Christopher Griffiths |
| 20 minutes | Psoriasis and psoriatic arthritis: Can remission be achieved?  
Speaker: Prof. Philip Mease | 20 minutes | Psoriasis patients: on the move  
Speaker: Lars Ettarp, President of IFPA |
| 20 minutes | Imaging: assessing severity and activity of psoriatic arthritis by ultrasonography, MRT and CT  
Speaker: Ass. Prof. Fiona McQueen | 16.30 – 16.45 | **CLOSE OF SCIENTIFIC PROGRAM** |
| 10 minutes | Abstract presentation  
Abstract No: 115 - Quality of care and research profiles. Results of an International Psoriasis Council (IPC) exercise | 16.30 – 16.45 | **CLOSE OF SCIENTIFIC PROGRAM** |

**SUNDAY JUNE 28TH**

IFPA informal member meeting  
World Psoriasis Day Supporters meeting - Closed meeting
Looking to the future in Psoriasis

Visit us at our Booth
at the 2\textsuperscript{nd} World Psoriasis
& Psoriatic Arthritis
Conference 2009
Registration

On-site registration
For on-site registration and/or questions, please contact the registration desk. The registration desk will open Wednesday June 24, 15.00-18.00. From 07.30 Thursday June 25 and will remain open all through the conference.

Registration Fees
Includes 25% VAT.

On site fee
Delegates SEK 7500
Nurses and other health professionals SEK 6875
Students* and IFPA Members SEK 3440
Accompanying person fee (incl 25 %VAT) SEK 1875

*Student fee: Please include letter of introduction from your department chairman.

Delegate Fee Covers
Participation in conference sessions, satellite symposium, welcome reception, exhibition, afternoon coffees, poster sessions and the Stockholm City Hall reception and subsidized fee for the conference dinner.

Accompanying Person’s Fee Covers
Participation in the welcome reception, poster session, the Stockholm City Hall reception and subsidized fee for the conference dinner.

Payment
Please contact the registration desk for any questions regarding your payment.

Accommodation
Please contact the registration desk for any questions regarding your hotel accommodation. The official conference hotels are: Scandic Norra Bantorget, Best Western Hotel Terminus, Hotell Lilla Rådman-nen, Comfort Hotel Stockholm, Nordic Sea Hotel, Clarion Hotel Sign, Rica Hotel Kungsporten, Rica Hotel Stockholm, Freys Hotel, Sheraton Stockholm, Hotel Tegnérlunden, Bentley Hotel

Important addresses

Conference & Exhibition Secretariat
MCI Stockholm Office
P.O. Box 6911
SE-102 39 Stockholm, Sweden
Phone: +46 8 5465 15 00
Fax: +46 8 5465 15 99
E-mail: psoriasis2009@mci-group.com

All correspondence to members of the Organizing Committee may be sent to the Conference secretariat for further distribution.

Program Information
Veronika Lindberg
Phone: +46 8 556 109 10
E-mail: veronika.lindberg@pso.se

IFPA Secretariat
Box 5173
SE-121 18 Johanneshov
SWEDEN
Phone: +46 8 556 109 14
Fax: +46 8 556 109 19
E-mail: ifpa@pso.se

Abstract Secretariat
Bruce F. Bebo Jr., Ph.D.
National Psoriasis Foundation, USA
E-mail: bbebo@psoriasis.org

Conference web site
www.ifpa-pso.org

Photo by Olof Holdar
That’s 361 days to focus on life... not psoriasis

Introducing the first in a new class of biologics that selectively target IL-12 and IL-23 for the treatment of moderate-to-severe plaque psoriasis

Read more about Stelara® at www.stelara.se

Stelara (ustekinumab) Solution for injection, 45 mg/0.5ml. (Currently unavailable: 90 mg/1ml.) Rx. LEAPACOS. Indication: STELARA is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA. Packaging: 1 vial, 45 mg/0.5 ml. Subvention: No. Stelara is filed for reimbursement in the Pharmaceutical Benefits Scheme in Sweden on 6 February 2009. For full SPC and prices, go to www.fass.se
Welcome Reception
Wednesday June 24 at 18:00 hrs

The welcome reception will take place at City Conference Centre/Folkets Hus. Wine, soft drinks and snacks will be served. Included in the registration fee for delegates and accompanying guests only if marked on the registration form.

Reception, Stockholm City Hall
Thursday June 25 at 19:00 hrs

The City of Stockholm and the Stockholm County Council invite you to a buffet dinner at the Stockholm City Hall. Beautifully situated on the waterfront of Riddarfjärden in central Stockholm. The Stockholm City Hall is mostly famous for the Nobel Prize festivities, which take place in the Blue Hall every year on December 10.

Please bring the invitation card included in your delegate kit. Individual transport to and from the City Hall is located approximately within 15 minutes walking distance from the conference venue.

Conference Dinner
Friday June 26 at 19:30 hrs The Opera Terrace

Welcome to an unforgettable evening in one of Stockholm’s most famous restaurants. The Opera Terrace, located on the second floor of Operakällaren, offers visitors a magnificent view of the Royal Palace, the Swedish Parliament and the surrounding waters through the panoramic windows. We will be served a first class three course conference dinner and enjoy delightful entertainment during the evening. Take this opportunity to network with fellow colleagues from all over the world.

Price: SEK 700

Social Program

- All events are available for delegates and accompanying persons and should have been prebooked on the registration form. For late bookings - please contact the registration desk for availability.
- A ticket is mandatory for entrance and will be handed out at the registration desk.

Photo by Richard Ryan
Looking Deeper Into Psoriasis and Nail Disease

AGENDA

12:15 – 12:20  Welcome and Introductions
Jean-Hilaire Saurat, MD, Chair
Geneva University Hospital - Geneva, Switzerland

12:20 – 12:35  Psoriasis and Systemic Inflammation:
Underdiagnosed Enthesopathy
Giampiero Girolomoni, MD
University of Verona - Verona, Italy

12:35 – 12:50  The Nail as a Skeletal Appendage—
Implications for Understanding
the Link Between Psoriasis and
Arthritis
Dennis McGonagle, MB, FRCPI, PhD
University of Leeds - Leeds, United Kingdom

12:50 – 13:05  Approach to Managing Patients
With Nail Involvement
Alexandra Ogilvie, MD
Universität Erlangen - Erlangen, Germany

13:05 – 13:15  Question-and-Answer Session
Session Panel

Thursday, 25 June 2009
12:15 – 13:15
The Auditorium Norra Latin
Stockholm City Conference Center
Stockholm, Sweden

A light lunch will be set up in the Auditorium
Foyer from 12:00 – 12:15.

Photos courtesy of Prof Dennis McGonagle
Audio-visual facilities
All lecture halls will be equipped with PC computer projectors.

Badges
The delegates name badge will be provided at the registration desk. All delegates are requested to wear the badge throughout the Conference. Only badge holders will be admitted to the sessions.

Business hours & shopping
Shops are open between 10.00 and 18.00 hrs on weekdays and from 10.00 to 15.00 hrs on Saturdays. Shops in the City centre have extended opening hours, some even on Sundays between 12.00 and 16.00 hrs.

The main shopping streets in the centre of Stockholm are: Hamngatan, Biblioteksgatan, Drottninggatan and Västerlånggatan in the Old Town.

Certificate
You will find a Certificate of Attendance in your conference bag.

Climate and clothing
The average temperature in June is around 18°C (64°F)

CME Credits
EACCME and CME credit hours may be awarded for participation in the conference. An amount of 18 CME credit hours will be awarded for participation in the complete program. You can receive a CME certificate upon request at the registration desk.

Credit cards
International credit cards are accepted for payments in hotels, restaurants and shops.

Conference venue
The conference will be held at City Conference Centre/Folkets Hus and Norra Latin, between June 24-28, 2009. Address: Barnhusgatan 12-14. The conference venue is located in the centre of Stockholm, within walking distance from the Central Station. For further information please visit the conference venue web site: www.stoccc.se

Currency
The currency in Sweden is the Swedish krona, SEK.
1 Euro = 10.37 SEK
1 USD = 7.66 SEK
(Currency rate as per May 2009.)
Currency calculation can be found on-line at www.x-rates.com

Exhibition
The Exhibiting companies are:
- Abbott
- EUROSPO
- Galderma Nordic
- H.Waldmann
- IFPA, World Psoriasis day
- Janssen Cilag
- LEO Pharma Sweden
- Psoriasis Association in Stockholm
- Quantel derma
- Saalmann
- Sandoz
- Schering-Plough
- Spa Smrdaky, Slovakia
- Tinefcon, Piramal Life Sciences
- Wyeth
- Wyeth Naked Truth

The Exhibition will be open for delegates on Thursday, June 25, 07.30-17.30, Friday 07.30-17.30 and Saturday 07.30-16.45.

Evaluation
After the conference you will receive an evaluation form by e-mail. Your opinion is very important for us and we appreciate that you take your time to fill it out.

Insurance
Neither the Conference Organizers or the Conference Secretariat accepts any liability for personal injuries sustained, or for loss or damage to property belonging to conference participants, either during or as a result of the conference.

All delegates are strongly advised to obtain their own insurance before travelling to the conference.

Language
The official conference language is English. No simultaneous interpretation will be made.

Meals
Afternoon coffee will be served on the premises. Lunches are not included in the registration fee. However, there are several restaurants in the vicinity of the conference venue.

Press
Authorized members of the press are welcome to cover the 2nd World Psoriasis and Psoriatic Arthritis Conference. All press is welcome to register and use the on-line form. You will be asked to show your press identification at the venue.

Speaker’s ready room
Please bring your PowerPoint presentation on a CD-rom or a USB memory stick and deliver it to the technician in the Speakers’ ready room, room nr 401. This can be done between 8 am to 4 pm during the conference but at least 2 hours before your session starts.

Time zone
Sweden is 1 hours ahead of Greenwich Mean Time (GMT)

Tourist information
For tourist information on Stockholm and Sweden: Tourist Center in ‘Sweden House’ (SverigeHuset) at Kungsträdgården.
E-mail: info@svb.stockholm.se
website: www.stockholmtown.com
Make hiding from plaque psoriasis part of the PAST

A clearer FUTURE can begin with ENBREL

When you choose ENBREL, for your plaque psoriasis patients, you choose experience

- 16 years of collective clinical experience
- Over 1.6 million patient-years of collective clinical experience
- Experience in over 105,000 plaque psoriasis and psoriatic arthritis patients
- Established safety profile in both adult and pediatric plaque psoriasis patients

The #1-selling biologic worldwide across its approved indications

Indications

ENBREL is indicated for the treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.

ENBREL is indicated for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

ENBREL is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. ENBREL has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.

Important Safety Information

Serious infections, including tuberculosis, and sepsis have been reported. Some of these infections have been fatal.

Do not start ENBREL in the presence of allergy to ENBREL or its components.

There have been rare reports of CNS demyelinating disorders, although the causal relationship to ENBREL remains unclear.

For more information, please refer to the ENBREL Summary of Product Characteristics.

Welcome to Stockholm, the Royal Capital of Sweden. Discover a city like no other - a city built on 14 islands, where you are never far from the water. Well-preserved medieval buildings stand alongside modern architecture. Stockholm is also home of the Nobel Prize. And just outside the city, the archipelago of 24,000 islands is waiting to be explored.

Stockholm is a city of contrasts - water and islands, history and innovation, small town and big city, short winter days and long, light summer nights - with a dazzling array of impressions. Thanks to the city’s compact size, you can see and do most things in a short space of time - which makes it a perfect destination for city breaks or longer stays, all the year round.

Discover a city of contrasts. Go back 750 years in time and feel the medieval atmosphere of the Old Town “Gamla Stan” as you wander through the narrow streets. Stockholm has got history - but also the latest in fashion and IT. The trendy Stockholmers are often used as a test market by international companies, as they are quick to pick up on the latest trends.

Stockholm is one third water, one third green belt and one third city. The island of Djurgården, the world’s first National City Park, is only a short walk from the pulse of the inner city.

Stockholm is very well positioned with most of Europe within three hours reach. It is a genuine meeting point in every respect and an increasingly important hub for flights to major destinations in the Baltic Sea Region, European Union and the expansive global community.

Sweden is the fourth largest country in Europe. Nearly 100,000 lakes dot the Swedish countryside, which is relatively flat apart from a long mountain chain in the north. There are thousands of islands off the jagged coast and the warm Gulf Stream in the Atlantic provides Sweden with a milder climate than other countries situated equally far north. Stockholm, the capital, is at almost the same latitude as southern Greenland but has an average temperature of approx. +18°C (64°F) in June. Above the arctic circle, you can also experience the midnight sun, when the sun never sets.
Photographic Exhibition

Psoriasis: The Naked Truth is a pan-European educational programme to raise awareness of the physical and emotional impact of psoriasis. The centrepiece of Psoriasis: The Naked Truth is a photo exhibit that captures the experience of living with psoriasis through photography and personal stories.

“I wanted to show off my body just as it is, without any shame, and to show that even with psoriasis we can be beautiful.”

Maria Javiera, 26, Chile

Wyeth created and funded Psoriasis: The Naked Truth, a pan-European educational programme.
Abstract Titles

Genetics, genomics and proteomics

1. KIR genes in Portuguese patients with psoriasis vulgaris
   Tango Torres1, Patricia Rodrigues2, Clara Peres1, Paulo Costa1, Berta Martins1, Manuela Soares1
   1CHP-ISA, 2CEBAS-UP, 3Dermatology Department CHP-ISA, Portugal

2. A genome-wide linkage scan of familial psoriasis: linkage to chromosome 2
   Nejib Doss3, Cindy Helms4, Mourad Mokni5, Anne Bowcock6
   1) Karolinska Institutet, Sweden 2) Harvard University, Boston, United States 3) La Rabita Hospital, Tunisia 4) Washington University - Saint Louis, United States

3. Heritability in psoriatic arthropathies in five generations. The Reykovjak psoriatic arthropathy study.
   Bjorn Godfroffson1, Thordur Jon Love2, Ari Karason2
   1) University Hospital, Iceland 2) Harvard University, Boston, United States 4) DECOD Genetics, Iceland

4. The molecular profile of psoriatic skin in responders to ustekinumab or etanercept following twelve weeks of treatment in a double blind trial
   James Kruer1, Katherine Lee2, Frederik Barbiad3, Mayte Suarez-Fannas4, Carrie Brodemarkel5
   2) Rockefeller University, 1) Centor Research and Development, Inc., United States

5. Association between the PTNP22-185C/T polymorphism and Psoriatic Arthritis
   Kristina Janekl1, Maritn Johannsson1, Sibbritt Rantapaa Dahlgqvist1, Grad-manne Alenius1
   1) Dept of Rheumatology, Umeå, Sweden

6. Simple and rapid screening for HLA-Cw*06 in psoriatic patients from Poland
   Aneta Szczekowsk Dobosz1, Aneta Szczekowska Dobosz1, Krzysztof Rebala1, Joanna Wysocka1
   1) Medical University of Gdańsk, Poland

7. A Quantitative analysis of digitopalmar dermatographic lines in 400 Psoriatic and Psoriatic arthropathies patients from Croatia
   Miljenko Cvetcan1, Dasic Zrinka1, Dasic Iv1
   1) Zagreb Rehabilitation Center, 2) University Department of Physical Medic, Croatia

8. HLA and KIR gene frequency in a multiethnic psoriatic and psoriatic arthropit patients.
   Sueli Carneiro1, Flavia Cassia1, Danielli Cristina Oliveira2, Anna Abou-Raya1, Suzan Abou-Raya1
   1) Landspitali University Hospital, 2) PhD student, 3) Dermatologist, 4) ENT surgeon, Iceland 5) Assistant Professor, Dermatologist.

9. Comorbidities in Psoriasis
   Majed Khraishi1, Sarah Maclaughlin1, Gerry Mugford1, Neil Mchugh1
   1) Abbott Laboratories, 2) Analysis Group, Inc., United States

    Shiraz R Gupta3, Yanjun Bao1, Ulrich Mrowietz3
    1) University Hospitals of Erlangen, 2) Univ.Hautklinik Leipzig, 3) Department of Dermatology Erlangen, Germany

11. SCID mouse-human skin chimera: A unique animal model for Psoriatic Arthritis seek about their condition?
    Shiraz R Gupta3, Yanjun Bao3, Parvez M Mulani3
    1) Radboud University Medical Centre, Netherlands 2) VA Medical Center Northeast Ohio.

Pathophysiology and Immunobiology

9. Seric and synovial fluid values of cytokines in psoriasis lesions and psoriatic arthritis patients from Poland
   Anna Sczerkowski Dobsz1, Anna Sczerkowska Dobosz1, Krzysztof Rebala1, Joanna Wysocka1
   1) Medical University of Gdańsk, Poland

10. Th-17 cells in psoriatic disease: Studies in developing psoriatic lesions and psoriatic arthritis patients
    Sibbritt Rantapaa Dahlgqvist1, Grad-manne Alenius1
    1) Dept of Rheumatology, Umeå, Sweden

11. Protein kinase C-dependent upregulation of miR-203 during keratinocyte differentiation
    Emiko Sonoky1, Eniko Sonoky1, Tanning Wei1, Elizabeth Pavez Loez1, Hans Torm1, Manna Ståhle1, Andor Pirvacs1
    1) Karolinska Institutet, 2) Uppsala University, Sweden

12. Atypical lymphocytes in patients with psoriasis: Studies in develop-
    lens and psoriatic arthritis patients.
    Xiaolan Wei1, Torma Hans1, Hao Li1, Andor Pirvacs1, Manna Ståhle1, Eniko Sonoky1
    1) Karolinska Institutet, 2) Uppsala University Hospital, Sweden

13. Neuroal changes in psoriasis exacerbation
    Kristina Jonckheere1, Armo Van Kuik1, Cristina Lebha1, Maartje Boumjans1, Danielle Serlaj1, Paul-Tak1
    1) AMC, Netherlands

Epidemiology

22. Impact of spondyloarthritis on patients with chronic psoriasis
    Helga Valdimarra1, Ragna Thorleifsdottir2, Jon Olafsson3, Bardur Sigurgeirsson3, Hannes Petersen4, Andrew Johnstone1
    1) Landspitali University Hospital, 2) PhD student, 3) Dermatologist, 4) ENT surgeon, Iceland 5) Assistant Professor, United States

23. Body weight and smoking associates with onset of plaque psoriasis: a population based case-control study.
    Katrinna Wolk1, Lotus Malbris1, Petra Kjell1, Katarina Wolk1, Lotus Malbris1, Katarina Wolk1
    1) Bath Institute for Rheumatic Diseases, 2) RNHRD, United Kingdom

24. Prevalence of articular involvement in patients with psoriasis
    Rieke Driessen1, Delia Diaconu1, Rieke Driessen1, Peter Van De Kerkhof1, Piet Van Riel1, Jaap Fransen1, Elke De Jong1
    1) Radboud University Medical Centre, Netherlands

25. What information do patients with Psoriatic Arthritis seek about their condition
    Shiraz R Gupta3, Yanjun Bao1, Ulrich Mrowietz3
    1) Radboud University Medical Centre, Netherlands 2) VA Medical Center Northeast Ohio.

26. Increased Risk of Psychiatric Disorders in a Pediatric Population With Psoriasis
    Alexa B Kimball1, Elisabeth Guevara-Gutierrez1, Mistolinsa Zolano-Oroz1, Gabriela Briseño-Korman1
    1) University Hospitals of Erlangen, 2) University Hospital of Pediatatia IMSS, Mexico

27. The expression of microRNA 203 during human skin morphogenesis
    Xianlan Wei1, Torma Hans1, Hao Li1, Andor Pirvacs1, Manna Ståhle1, Eniko Sonoky1
    1) Karolinska Institutet, 2) Uppsala University Hospital, Sweden

28. Mortality in Psoriatic Arthritis - A UK Perspective
    Christine Dutton1, Charlotte Cavall1, Gordon Taylor2, Hazel Kay1, Nicola Waldron1, Eleanor Kurendowycz1, Neil Mchugh1
    1) NHRI, 2) University of Bath, United Kingdom

29. Psoriasis treatment patterns of dermatologists in Northeast Ohio.
    I Grodez2, L Coa3, K Kvick2, RP Brodell3, En Mostow3, N Korman1
    1) Murdugh Family Center for Psoriasis, United States

30. Psoriatic arthropathy care at two German university hospitals - results of an epidemiological review
    Stefanie Heimann1, Inka Hillens1, Andreas Collman1, Michael Sticherling1
    1) University Hospitals of Erlangen, 2) Univ Hautklinik Leipzig, 3) Department of Dermatology Erlangen, Germany

31. Psoriatic arthritis prevalence in Mexican patients with Psoriasis attending a third level dermatological institute.
    Jose Fernando Barba-Gomes1, Elizabeth Guevara-Gutierrez1, Mistolinsa Zolano-Oroz1, Gabriela Briseño-Korman1, Gabriela Guevara-Nunez1, Alberto Tlacuit-Pieira2, Sergio Gutierrez-Brena1
    1) Instituto Dermatologico de jalisco, 2) IMSS Hospital de Pediatatia IMSS, Mexico

32. Analysis of Factors associated with Obesity in Psoriatic Arthritis
    Allen Anandarajah1, Christopher Mitchelin1
    1) University of Rochester Medical Center, United States

Comorbidities

33. Comorbidities in Psoriasis
    Nora Kogan1, Rosana Veira1, Elena Chaparro1, Alejandro Crespi1, Simón Guss1, Mercedes Hassan1
    1) Argentina

    Ramin Saheri1, Behnaz Behnami1
    1) Iran

35. Psoriasis and comorbidities during a two years evaluation
    Caius Solomon1, Esther Barbac1
    1) University of Medicine and Pharmacy, Romania

36. Cardiovascular comorbidity in patients with psoriasis
    Javarka Delic1, Javarka Delic1, Vesna Vish钦ovi1, Nada Pantolic1
    1) City Institute for Dermatology, 2) Serbia

37. Adalimumab induced psoriasis of the scalp resulting in extensive non-scarring and scarring alopecia
    Laela El Shabani-Caen1, Michelangelo Laplacca1, Colina Vincenzino1, Thomas Hadd1, Robert Mullegger1, Antonella Tosti1
    1) Italy

38. Rheological properties of blood as a marker of inflammation and cardiovascular risk in psoriatic arthritis.
    Tatiana Karotova1, Elena Loginova1, Diana Novikova1, Lev Denisov1, Hodeida Klimova1, Elena Aleksandrova1, Evgeny Nasonov1
    1) Institute of Rheumatology of RAMS, Russian Federation

39. Comorbidity Prevalence in Psoriasis Patients: A Meta-Analysis
    Pavel Malini1, Anna Guerin1, Andrew P Yu1, Eric Q Wu1, Shira R Gupta1, Yanjun Bao1, Ulrich Mrowietz1
    1) Abbott Laboratories, 2) Analysis Group, Inc., United States

40. Comorbidities in a psoriatic arthritis cohort.
    Majed Khraishi1, Sarah Maclaughlin1, Gerry Mugford1, Karen White1
    1) Memorial University of Newfoundland, 2) Nexus Clinical Research, Canada

41. Metabolic syndrome at psoriasis onset and at long-term follow-up of psoriasis: A prospective cohort study
    Lotus Malbris1, Lotus Malbris1, Katharina Wolk1, Petra Kjell1, Tomas Nordquist1, Manna Ståhle1
    1) Karolinska Institutet, 2) Uppsala University, Sweden

42. Inflammation: A pivotal link between Psoriatic Arthritis and Atherosclerosis
    Anna Abou-Raya1, Suzan Abou-Raya2
    1) University of Alexandria, Egypt
97. Depressive Symptoms and Quality of Life in Psoriatic Patients with Different Lesion Localizations
Korand Janowski, Stanislawowa Steuden
1) Catholic University of Lublin, 2) Medical university of Lublin, Poland

98. Coping Strategies and Disease-Related Appraisals in Psoriatic Patients with Different Lesion Localizations
Korand Janowski, Stanislawowa Steuden
1) Catholic University of Lublin, Poland

99. Development of a composite Disease Activity score in Psoriatic Arthritis
Aizad Mumtaz, Phil Gallagher, Brian Kirby, Laura C. Coates, Robin Warram, Phillip Hellowell, Oliver Fitzgerald
1) St Vincents University Hospital Dublin, 2) St Vincents University Hospital, Ireland

100. PATIENT PARTICIPATION IN RESEARCH, A SWEDISH MODEL
Nina Hemmestad Linderfeldt
1) Sweden

101. Psoriasis social network website www.psoriasis-patients.com
Richard Thomas, Roman Biond
1) Micromedica.com, 2) Canada

102. Evaluation of the quality of life in 200 Brazilian psoriatic patients.
Sueli Carneiro, Manuela Maria Azapais, Bruna Darceri, Fabiana Torres, Maria Chaves, Gustavo Veronardi, Marcia Rios e Silva
1) Federal University of Rio de Janeiro, 2) State University of Rio de Janeiro, Brazil

Clinical Cases

103. Borrelia mimicking lupus-like syndrome during infliximab treatment
Sunja Moller, Jorg C. Praza
1) Ludwig-Maximilians-University, Germany

104. Development of vical warts in a patient receiving TNP- inhibitor etanercept
Tia Oktar, Galina Velho, Madalena Sanches, Manuela Soares
1) CHP- HSA, 2) Dermatology Department CHP-HSA, Portugal

105. Effectiveness of Treatment with Infliximab in a subject suffering from psoriasis and personality disorder borderline
Rosella Filippetti
1) Uoc dermatologico ospedale frascati roma, Italy

106. Psoriasis vulgaris and extremitas cutanea sarcoidosis: A case report
Moustafa Amara, Ahmet Akar, Haikan Ebibi, Ibrahim Ozmen, Erol Koc, Seyfettin Gunes
1) Gulhane Military Medical Academy, 2) GATA Dermatology, 3) GATA Chest and Tuberculosis, Turkey

107. Immunophenotype of the inflammatory infiltrate and epidermis cellular regeneration in the psoriatic papule
Vitaly Olokhopyov, Ola Pravdina
1) The Omsk State Medical Academy, 2) Russian Federation

108. Reasonableness for systemic immunosuppressive drugs administration in treatment of patients with psoriasis
Vitaly Olokhopyov, Elena Zubareva
1) The Omsk State Medical Academy, Russian Federation

Aida Pasic, Gordana Krstevici, Goran Maricsic, Aida Pasic, Kresimir Kostovic
1) University Hospital Center Zagreb, 2) Napatalan Spec. Hospital for Med. Rehab., Croatia

110. Continuous antipsoriatic treatment with infliximab (IFX) throughout 8 years - a case report
Antje Wedgew, Gottfried Wozel
1) University Hospital Carl Gustav Carus, Germany

111. Childhood Generalized Pustular Psoriasis: A Report on Seven Cases
Ricardo Romiti, Sarah Oliveira, Mariana Raimo, Andreia Ribeiro, Maria Luigia De Bonis, 1) Ministry of the Interior, 2) Univ. Of Medicine and Pharmac Colledge, 3) Lynde Centre for Dermatology, 4) Abbott Healthcare, Brazil

112. Health Economics and Health Policies

113. Employment is maintained and sick days decreased with etanercept in psoriasis/psoriatic arthritis patients
Robert Gisnadecki, Tapani Tuominen, Sarolta Karpati, Deborah Robertson, Bruce Freundlich 1), Charles Malta, Robert Boggs
1) Helsinki University Hospital, Denmark 2) Hannanpaa City Hospital, Finland 3) Semmelweis University, Hungary 4) Wethy Research, United States

114. Statistics in the treatment of psoriasis - friend or foe?
Andreas Colman, Michael Sticherling
1) University Hospitals of Erlangen, Germany 2) Department of Dermatology Erlangen, pigzlar

115. Quality of care and research profiles: Results of an International Psoriasis Council (IPC) exercise
Elizabeth Hori, Jonathan Barker, Richard Langley, Alan Menter, Alexia Kimball
1) International Psoriasis Council, United States 2) St. John’s Institute of Dermatology, United Kingdom 3) Dahlhouse University, Canada 4) Bayler University Medical Center, 5) Harvard Medical School, United States

Late Breaking Abstracts

116. Adalimumab efficacy for psoriatic nail disease in BELIEVE.
D Thaci, J-P Ortonne, D Kragballe, J Nisarath, P Spreca, G Neure, H Kupper, H Sacu
1) Frankfurt, Germany 2) University of Nice, Nice, France 3) Athus Sygehus, Athus, Denmark 4) Hopitaux universitaire de Genève (HUG), Geneva, Switzerland 5) TEO Pharmaceutica Products Ltd. A/S, Ballerup, Denmark 6) Abbott GmbH & Co. KG, Ludwigshafen, Germany 7) Abbott Laboratories, Abbott Park, IL, USA
Dear Participant,
SAS, the Official Airline of 2nd World Psoriasis & Psoriatic Arthritis Conference welcomes you to Stockholm, and hope that you will have a most successful and enjoyable conference!

We look forward to welcoming you on board again.

www.flysas.com
A Conference Venue; Folkets Hus & Norra Latin
B City Terminal, arrival for Arlanda Express and buses from Arlanda Airport
C Stockholm City Hall
D Opera Terrace

The Official Hotels booked
1 Best Western Hotel Terminus
2 Comfort Hotel Stockholm
3 Hotell Lilla Rådmannen
4 Clarion Hotel Sign
5 Rica Hotel Kungsgatan
6 Rica Hotel Stockholm
7 Freys Hotel
8 Sheraton Stockholm
9 Hotel Tegnérlunden
10 Bentley Hotel
11 Scandic Norra Bantorget
12 Nordic Sea Hotel
Welcome to IFPA

WORLDWIDE UNITY FOR PEOPLE LIVING WITH PSORIASIS

INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS